BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34246718)

  • 21. Glycyrrhiza glabra (Licorice) root extract attenuates doxorubicin-induced cardiotoxicity via alleviating oxidative stress and stabilising the cardiac health in H9c2 cardiomyocytes.
    Upadhyay S; Mantha AK; Dhiman M
    J Ethnopharmacol; 2020 Aug; 258():112690. PubMed ID: 32105749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stimulating basal mitochondrial respiration decreases doxorubicin apoptotic signaling in H9c2 cardiomyoblasts.
    Deus CM; Zehowski C; Nordgren K; Wallace KB; Skildum A; Oliveira PJ
    Toxicology; 2015 Aug; 334():1-11. PubMed ID: 25997894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Doxorubicin-induced cardiotoxicity involves IFNγ-mediated metabolic reprogramming in cardiomyocytes.
    Ni C; Ma P; Wang R; Lou X; Liu X; Qin Y; Xue R; Blasig I; Erben U; Qin Z
    J Pathol; 2019 Mar; 247(3):320-332. PubMed ID: 30426505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cannabidiol Protects against Doxorubicin-Induced Cardiomyopathy by Modulating Mitochondrial Function and Biogenesis.
    Hao E; Mukhopadhyay P; Cao Z; Erdélyi K; Holovac E; Liaudet L; Lee WS; Haskó G; Mechoulam R; Pacher P
    Mol Med; 2015 Jan; 21(1):38-45. PubMed ID: 25569804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Candidate early predictive plasma protein markers of doxorubicin-induced chronic cardiotoxicity in B6C3F
    Desai VG; Lee T; Moland CL; Vijay V; Han T; Lewis SM; Herman EH; Fuscoe JC
    Toxicol Appl Pharmacol; 2019 Jan; 363():164-173. PubMed ID: 30517846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dosing depending on SIRT3 activity attenuates doxorubicin-induced cardiotoxicity via elevated tolerance against mitochondrial dysfunction and oxidative stress.
    Yang N; Ma H; Jiang Z; Niu L; Zhang X; Liu Y; Wang Y; Cheng S; Deng Y; Qi H; Wang Z
    Biochem Biophys Res Commun; 2019 Sep; 517(1):111-117. PubMed ID: 31303273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardioprotection against doxorubicin by metallothionein Is associated with preservation of mitochondrial biogenesis involving PGC-1α pathway.
    Guo J; Guo Q; Fang H; Lei L; Zhang T; Zhao J; Peng S
    Eur J Pharmacol; 2014 Aug; 737():117-24. PubMed ID: 24858368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Knockdown of Mtfp1 can minimize doxorubicin cardiotoxicity by inhibiting Dnm1l-mediated mitochondrial fission.
    Aung LHH; Li R; Prabhakar BS; Li P
    J Cell Mol Med; 2017 Dec; 21(12):3394-3404. PubMed ID: 28643438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. (-)-Epigallocatechin-3-gallate alleviates doxorubicin-induced cardiotoxicity in sarcoma 180 tumor-bearing mice.
    Yao YF; Liu X; Li WJ; Shi ZW; Yan YX; Wang LF; Chen M; Xie MY
    Life Sci; 2017 Jul; 180():151-159. PubMed ID: 27956351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitophagy inhibitor liensinine suppresses doxorubicin-induced cardiotoxicity through inhibition of Drp1-mediated maladaptive mitochondrial fission.
    Liang X; Wang S; Wang L; Ceylan AF; Ren J; Zhang Y
    Pharmacol Res; 2020 Jul; 157():104846. PubMed ID: 32339784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of doxorubicin and its analogue mitoxantrone on cardiac muscle and on serum lipids: an experimental study.
    Koutinos G; Stathopoulos GP; Dontas I; Perrea-Kotsarelis D; Couris E; Karayannacos PE; Deliconstantinos G
    Anticancer Res; 2002; 22(2A):815-20. PubMed ID: 12014656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy.
    Carvalho RA; Sousa RP; Cadete VJ; Lopaschuk GD; Palmeira CM; Bjork JA; Wallace KB
    Toxicology; 2010 Apr; 270(2-3):92-8. PubMed ID: 20132857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitochondrial Targeting of Doxorubicin Eliminates Nuclear Effects Associated with Cardiotoxicity.
    Jean SR; Tulumello DV; Riganti C; Liyanage SU; Schimmer AD; Kelley SO
    ACS Chem Biol; 2015 Sep; 10(9):2007-15. PubMed ID: 26038829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio.
    Childs AC; Phaneuf SL; Dirks AJ; Phillips T; Leeuwenburgh C
    Cancer Res; 2002 Aug; 62(16):4592-8. PubMed ID: 12183413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity.
    Oliveira PJ; Bjork JA; Santos MS; Leino RL; Froberg MK; Moreno AJ; Wallace KB
    Toxicol Appl Pharmacol; 2004 Oct; 200(2):159-68. PubMed ID: 15476868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adiponectin agonist ADP355 ameliorates doxorubicin-induced cardiotoxicity by decreasing cardiomyocyte apoptosis and oxidative stress.
    Zhao D; Xue C; Li J; Feng K; Zeng P; Chen Y; Duan Y; Zhang S; Li X; Han J; Yang X
    Biochem Biophys Res Commun; 2020 Dec; 533(3):304-312. PubMed ID: 32958254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53.
    Zhang C; Feng Y; Qu S; Wei X; Zhu H; Luo Q; Liu M; Chen G; Xiao X
    Cardiovasc Res; 2011 Jun; 90(3):538-45. PubMed ID: 21278141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasmatic and chamber-specific modulation of cardiac microRNAs in an acute model of DOX-induced cardiotoxicity.
    Gioffré S; Ricci V; Vavassori C; Ruggeri C; Chiesa M; Alfieri I; Zorzan S; Buzzetti M; Milano G; Scopece A; Castiglioni L; Sironi L; Pompilio G; Colombo GI; D'Alessandra Y
    Biomed Pharmacother; 2019 Feb; 110():1-8. PubMed ID: 30453253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Altered mitochondrial epigenetics associated with subchronic doxorubicin cardiotoxicity.
    Ferreira A; Cunha-Oliveira T; Simões RF; Carvalho FS; Burgeiro A; Nordgren K; Wallace KB; Oliveira PJ
    Toxicology; 2017 Sep; 390():63-73. PubMed ID: 28865727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of cytochrome C oxidase-va is possibly involved in metallothionein protection from doxorubicin cardiotoxicity.
    Merten KE; Feng W; Zhang L; Pierce W; Cai J; Klein JB; Kang YJ
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1314-9. PubMed ID: 16144979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.